In other recent news, Recursion Pharmaceuticals reported its fourth-quarter 2025 earnings, delivering results that surpassed expectations. The company posted an earnings per share (EPS) of -$0.21, ...

Recursion is using AI to develop new drug candidates much more efficiently than the overall industry. Tempus AI's $1.27 billion trailing revenue comes from a clinical data flywheel that no competitor ...

Recursion has merged Exscientia’s AI-driven chemistry with its own phenomics and a new ClinTech real-world-data capability to streamline discovery and trials, consolidated R&D to five internal ...

Sat, March 21, 2026 at 10:45 AM UTC Drug discovery is broken. The industry average is 2,500 compounds synthesized over 42 months to find one development candidate. Recursion Pharmaceuticals (NASDAQ: ...

Recursion is using AI to develop new drug candidates much more efficiently than the overall industry. Tempus AI's $1.27 billion trailing revenue comes from a clinical data flywheel that no competitor ...

Recursion is using AI to develop new drug candidates much more efficiently than the overall industry. Tempus AI's $1.27 billion trailing revenue comes from a clinical data flywheel that no competitor ...

SALT LAKE CITY - Recursion (NASDAQ:RXRX) announced Monday that Vicki Goodman, M.D., will become Chief Medical Officer effective April 6, 2026, replacing David Mauro, M.D., Ph.D., who is transitioning ...

Nvidia's recent $700 million acquisition of Run:ai enhances GPU access and infrastructure flexibility. The acquisition of OctoAI for $250 million bolsters Nvidia's generative AI tools portfolio.

GPU behemoth Nvidia’s most important metric probably isn’t its data center revenue, hyperscaler capex trends, or the yield on its latest chips. It it is barely talked about by semiconductor analysts ...